Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272937 | 0.90 | SYK (0.58) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL3272940 | 0.90 | SYK (0.58) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL5218342 | 0.90 | SYK (0.58) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL25301720 | 0.89 | SYK (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL7360200 | 0.89 | CTRB1 (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL7496788 | 0.89 | SYK (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL25256638 | 0.89 | SYK (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL7360205 | 0.89 | CTRB1 (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL5197783 | 0.89 | SYK (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL12849405 | 0.89 | SYK (0.72) | SYKCTRB1CTSKATMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0669912-B1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | SYK 331/4885CTRB1 380/4885CTSK 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.